Literature DB >> 21265057

Pancreatic cancer: Gemcitabine confirmed as the first-line therapy for pancreatic cancer.

Claire Greenhill.   

Abstract

Entities:  

Year:  2011        PMID： 21265057     DOI： 10.1038/nrgastro.2010.200

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

Authors:  Laetitia Dahan; Frank Bonnetain; Marc Ychou; Emmanuel Mitry; Mohamed Gasmi; Jean-Luc Raoul; Stéphane Cattan; Jean-Marc Phelip; Pascal Hammel; Bruno Chauffert; Pierre Michel; Jean-Louis Legoux; Philippe Rougier; Laurent Bedenne; Jean-François Seitz
Journal:  Gut       Date:  2010-11       Impact factor: 23.059
  1 in total
  1 in total

1.  Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.

Authors:  Vasilios Karavasilis; Epaminontas Samantas; Georgia-Angeliki Koliou; Anna Kalogera-Fountzila; George Pentheroudakis; Ioannis Varthalitis; Helena Linardou; Grigorios Rallis; Maria Skondra; Georgios Papadopoulos; George Papatsibas; Joseph Sgouros; Athina Goudopoulou; Konstantine T Kalogeras; Christos Dervenis; Dimitrios Pectasides; George Fountzilas
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.